Photo by Michael D Beckwith on Unsplash
- As of July 6, 2026, 810 lawsuits involving Similac and Enfamil formula are pending in federal multidistrict litigation in Illinois — with hundreds more in state courts nationwide.
- The FDA has received zero manufacturer death-notification reports related to NEC going back to at least 2000, a 26-year gap confirmed by companies' own executives testifying under oath.
- Peer-reviewed research shows premature infants fed cow's milk-based formula are 6–10 times more likely to develop NEC compared to those exclusively breast-fed; among babies born after 30 weeks' gestation, confirmed NEC was 20 times more common in formula-only fed infants.
- Jury awards have been substantial: a Chicago jury awarded $70 million in April 2026; a Missouri verdict of $495 million against Abbott in July 2024 was upheld on appeal.
The Evidence
Zero. That is the number of infant death reports that formula manufacturers Abbott and Mead Johnson have ever submitted to the FDA for NEC-related fatalities — not in the last five years, not in the last decade, but stretching back more than 26 years, to at least 2000. As of July 6, 2026, an investigation by KFF Health News confirmed that this silence persisted even as federal law required manufacturers to notify regulators within 15 days whenever there was a "reasonable possibility" that their product had contributed to a death.
The Charlotte Post, citing reporting aggregated by Google News, brought renewed attention to one case that crystallizes the problem. In September 2016, a mother contacted Mead Johnson — manufacturer of the Enfamil brand — reporting that she believed their preterm formula had caused her infant's death from necrotizing enterocolitis (NEC), a catastrophic intestinal condition that destroys bowel tissue in vulnerable newborns. According to court documents, the company concluded there was "not a reasonable possibility" the formula was connected and closed the file. No FDA notification was filed.
The executives responsible confirmed as much under oath. Christina Valentine, who spent seven years as Mead Johnson's medical director for North America, testified in a 2024 deposition that she had never submitted an FDA death report for NEC during her entire tenure — even in cases where healthcare providers directly told the company they believed the formula was the cause. Abbott's former director of medical safety and surveillance, Fabrizis Suarez, offered parallel testimony in January 2024: he could recall no instance in which Abbott had notified the FDA that a baby had died of NEC potentially caused by Abbott's preterm formula during his 17 years at the company.
What makes this particularly striking, as KFF Health News documented, is that the reporting obligation is not discretionary. Federal rules require notification when there is a reasonable possibility of product involvement — a standard that, by any reasonable reading, was met repeatedly across decades of NEC deaths.
What the Research Actually Shows
The core scientific question in thousands of pending lawsuits is whether cow's milk-based formula meaningfully elevates a premature infant's risk of developing NEC. The peer-reviewed literature is consistent: yes, and by a substantial margin.
Premature infants fed cow's milk-based formula are 6–10 times more likely to develop NEC compared to infants who receive exclusively breast milk, according to research cited across the NEC litigation. Among babies born after 30 weeks' gestation specifically, confirmed NEC was 20 times more common in formula-only fed infants than in those who received any breast milk at all. These are not modest relative-risk adjustments of the kind that often dissolve under scrutiny — they are the kind of magnitude differences that would halt a pharmaceutical clinical trial at interim review.
The death toll reflects the scale of the problem. Between 2017 and 2023, approximately 2,300 newborns died from NEC in the United States, according to CDC data — roughly one infant per day. In 2022 alone, 356 infants died from the condition. As of July 6, 2026, the FDA, CDC, and NIH have issued a joint consensus statement on premature infant NEC risk, though the FDA continues to maintain there is "no conclusive evidence that preterm infant formula causes NEC."
It is worth naming the evidentiary nuance honestly: the studies linking formula to NEC are largely observational rather than randomized controlled trials (RCTs — the gold standard in clinical research where participants are randomly assigned to treatment or control groups). Ethical constraints make true RCTs nearly impossible here — researchers cannot randomly assign premature infants to formula when breast milk is available. But the signal is consistent across multiple independent studies, and the proposed biological mechanism — cow's milk proteins triggering inflammatory cascades in immature intestines — is biologically plausible and well-documented. Multiple juries have found it persuasive even as the FDA has not.
Photo by National Cancer Institute on Unsplash
What It Means for Families and for the Formula Industry
Chart: Two major jury verdicts against Abbott in NEC baby formula litigation. The $495 million Missouri award (July 2024) was upheld on appeal and remains the largest single verdict on record. The $70 million Chicago award (April 2026) covered four plaintiff families.
The financial stakes are substantial and still building. As of July 6, 2026, 810 Similac and Enfamil lawsuits are pending in a federal multidistrict litigation (MDL) proceeding — a legal consolidation mechanism that groups similar cases before one judge to improve efficiency — in the Northern District of Illinois. Hundreds of additional cases are proceeding in state courts across the country. With $495 million and $70 million verdicts already on the books, the aggregate exposure for Abbott and Reckitt Benckiser (which owns the Enfamil brand through its Mead Johnson subsidiary) is material by any measure.
Abbott has faced formula-related legal exposure on multiple fronts simultaneously. In June 2026, the Department of Justice closed its criminal investigation into Abbott related to a 2021–2022 Cronobacter bacterial outbreak that killed two infants, opting to recover money from federally funded nutrition programs rather than pursue criminal charges. Separately, a June 2026 recall of Nara Organics powdered formula — following three infant botulism cases spanning California, Pennsylvania, and Washington — added to an industry already absorbing intense regulatory and reputational pressure.
The legal picture contains genuine uncertainty in both directions. An Illinois appeals court in 2026 overturned a separate $60 million NEC verdict against Mead Johnson, ordering a new trial on the grounds that the trial judge had improperly instructed jurors about the company's duty to warn. That ruling does not erase the underlying liability theory, but it introduces meaningful variability into how individual cases will resolve. For investors tracking Abbott (ABT) and Reckitt Benckiser in their investment portfolio, the MDL docket in Illinois, the retrial on remand, and the possibility of tightened FDA adverse-event reporting requirements all represent ongoing headline risk with no near-term resolution date.
One angle worth flagging for anyone thinking about the longer-term regulatory picture: if the FDA responds to this litigation wave by mandating stricter adverse-event reporting for infant formula, compliance costs across the formula industry could rise significantly — potentially accelerating consolidation toward larger players better equipped to absorb those costs. That structural shift, if it materializes, would be a slow-moving but real input for financial planning decisions around consumer staples holdings.
How to Act on This
Speak directly with a neonatologist or pediatric gastroenterologist about the current evidence on breast milk versus formula for preterm infants. The research on NEC risk is substantial and worth a frank conversation with a qualified specialist — not a headline. This is not medical advice; it is a prompt to seek the right expert.
Statutes of limitations (the legal deadline by which a lawsuit must be filed) vary by state and typically begin running from the moment a family knew or reasonably should have known about a possible product connection — not necessarily from the date of injury. As of July 6, 2026, 810 cases are already in federal MDL proceedings. Consulting a mass tort attorney promptly is the right first step to determine whether you qualify and whether the window to file remains open in your state.
Review your investment portfolio for direct exposure to Abbott (ABT) and Reckitt Benckiser. Beyond the verdict totals, watch three specific signals: the outcome of the Mead Johnson retrial in Illinois, any FDA rulemaking proposals on formula adverse-event reporting, and the pace of MDL bellwether trials (early test cases that signal how the broader docket is likely to resolve). These are the data points that will move liability estimates — and by extension, share price and dividend risk — over the next several quarters.
Frequently Asked Questions
Can infant formula cause necrotizing enterocolitis (NEC) in premature babies?
Peer-reviewed research consistently finds that premature infants fed cow's milk-based formula are 6–10 times more likely to develop NEC compared to those fed exclusively on breast milk. Among babies born after 30 weeks' gestation, confirmed NEC was 20 times more common in formula-only fed infants than in those who received any breast milk. These are observational studies rather than randomized controlled trials — ethical constraints make true RCTs impossible here — but the signal is consistent and the biological mechanism is well-documented. The FDA as of July 6, 2026 maintains there is "no conclusive evidence" of causation, while multiple juries have found otherwise.
What is the baby formula NEC lawsuit settlement amount — and how large could the total get?
There is no global settlement as of July 6, 2026. Individual verdicts include $70 million awarded to four families by a Chicago jury in April 2026 and $495 million awarded against Abbott by a Missouri jury in July 2024, which was upheld on appeal. With 810 cases in federal MDL proceedings plus hundreds in state courts, total industry exposure could be substantial — though actual settlement amounts, if negotiations begin, will depend heavily on the outcome of the Mead Johnson retrial in Illinois and how appellate courts rule on pending appeals.
How do I qualify for the NEC baby formula lawsuit against Abbott or Mead Johnson?
NEC lawsuits have generally focused on premature infants who were fed Similac (Abbott) or Enfamil (Mead Johnson/Reckitt) formula in a hospital neonatal intensive care unit (NICU) and subsequently developed NEC. Each state has its own statute of limitations governing when a claim must be filed. If a premature infant in your family developed NEC and received cow's milk-based formula in a NICU setting, a mass tort attorney who handles baby formula NEC cases is the right first stop to assess eligibility and timing.
Bottom line: In my analysis, the most revealing element of this investigation is not the size of the verdicts — it is the 26-year absence of a single manufacturer death notification to the FDA, confirmed by the companies' own senior executives testifying under oath. That is not a clerical oversight; it is the predictable outcome of a regulatory framework that delegates surveillance to the parties with the most to lose from disclosure. My read is that the FDA's current "no conclusive evidence" position is increasingly untenable given the evidentiary record, and that some form of stricter adverse-event reporting requirement is more likely than not over the next two to three years. How aggressively the MDL proceeds — and whether a major settlement emerges before additional bellwether trials — will determine both the human and financial costs that follow. Families and investors alike should be watching the Northern District of Illinois docket closely.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, medical, or legal advice. Always consult qualified professionals before making investment, health-related, or legal decisions. Research based on publicly available sources current as of July 6, 2026.